Pharmaceuticals
PharmAbcine to present new interim data from its ongoing mTNBC trial at SABCS 2020
DAEJEON, South Korea, Dec. 7, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will present the updated interim data from the ongoing phase Ib trial of olin...
2020-12-07 21:00
1236
INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject in a Phase 2 clinical tr...
2020-12-07 21:00
3675
Antengene Announces Acceptance of IND Application in China for ATG-010 (selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
SHANGHAI and HONG KONG, Dec. 7, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and on...
2020-12-07 08:00
3667
CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
SHANGHAI, Dec. 6, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical company, announced updated safety and efficacy results from its ongoing global clinical studies of CT053, an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed an...
2020-12-06 19:00
3690
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China
SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced the advancement of clinical dev...
2020-12-04 21:00
8358
Samsung Biologics drives digital transformation with Plant 4 Virtual Showroom launch
INCHEON, South Korea, Dec. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced the launch of a virtual showroom to provide key features and real-time construction updates of its recently announced Plant 4. The digital showcase also highlights various specs and services that the S...
2020-12-04 20:00
2324
Polygiene and Eye-care innovator Body Doctor now increase the range of soothing eye compresses and face masks
STOCKHOLM, Dec. 4, 2020 /PRNewswire/ -- Body Doctor specializes in eye-care, eyelid hygiene products and have transformed the market for eye compresses and continue establishing a pedigree of bringing innovation to the sector with an antibacterial fabric thanks to the partnership with Polygiene®....
2020-12-04 16:23
2613
Ascentage Pharma Appoints Mr. Gang Zhu as Chief Commercial Officer to Lead Commercial Initiatives
SUZHOU, China and ROCKVILLE, Md., Dec. 4, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the appointment of Mr. Gang Z...
2020-12-04 08:28
2693
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
HANGZHOU and SHAOXING, China, Dec. 4, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolima...
2020-12-04 08:00
3932
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19
Highlights: * The first hospitalized patient with severe COVID-19, treated under an eIND was discharged in 5 days after being treated with Silmitasertib. * The first patient with moderate COVID-19 has enrolled into this clinical trial at the Center for Advanced Research and Education (CARE),G...
2020-12-03 22:17
2409
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
Partnership with leading global plasmid manufacturer advances INOVIO's INO-4800 Kaneka Eurogentec to support production of INO-4800 PLYMOUTH MEETING, Pa., Dec. 3, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to ...
2020-12-03 21:00
5827
Sihuan Pharmaceutical (0460) Won the Fifth "Listed Enterprises of the Year 2020" Presented by Bloomberg Businessweek/Chinese Edition
HONG KONG, Dec. 3, 2020 /PRNewswire/ -- Bloomberg Businessweek/Chinese Edition announced thatSihuan Pharmaceutical Holdings Group Ltd. (0460.HK) won the fifth "Listed Enterprises of the Year 2020". The event received enthusiastic support with enterprises from a wide range of industries participat...
2020-12-03 10:36
8600
WuXi AppTec Applauded by Frost & Sullivan for Its Unmatched Breadth of Expertise in Facilitating Early-stage Innovation and Clinical Research
The company accelerated clients' R&D and ensured agility by leveraging a global footprint, keen customer focus, and customized solutions. LONDON, Dec. 2, 2020 /PRNewswire/ -- Based on its recent analysis of the global contract research organization (CRO) market, Frost & Sullivan recognizes WuXi A...
2020-12-02 22:00
1647
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation
MUNICH and SHANGHAI, Dec. 2, 2020 /PRNewswire/ -- Tubulis, WuXi STA and WuXi Biologics today announced a strategic collaboration to manufacture and advance Tubulis' next generation antibody-drug conjugates (ADCs) towards IND-enabling studies. Tubulis has developed a dual platform approach to gene...
2020-12-02 19:00
2258
Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application
HONG KONG, Dec. 2, 2020 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce that Wanbang Pharmaceutical...
2020-12-02 18:35
10549
Central IVF Limited's Egg Donation Service Recognized as One of The Most Reputable in Australia
LONDON, Dec. 2, 2020 /PRNewswire/ -- Central IVF Limited has gone through a rebranding process emphasizing its leadership in the field of Egg Donation and representing the launching of its Donor Sperm service toAustralia. Donor Egg service has been rebranded as Central Egg Bank (CEB) and Donor S...
2020-12-02 16:44
1401
Ascentage Pharma Announces Clearances in China and the US for the Phase IIa Study of APG-115 Single Agent or in Combination with APG-2575 for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia
SUZHOU, China and ROCKVILLE, Md., Dec. 2, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Eval...
2020-12-02 08:09
2641
I-Mab Files Shelf Registration Statement for PIPE Investors
SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a registration statement on Form F-1 with the Securities and ...
2020-12-02 05:23
10037
Bora Pharmaceuticals completes acquisition of former GSK facility
MISSISSAUGA, ON, Dec. 1, 2020 /PRNewswire/ -- Bora Pharmaceuticals Co., Ltd announced today that the contract development and manufacturing organization (CDMO) has successfully completed the acquisition of GSK'sMississauga, Ontario (Canada) facility. Initially announced in March 2020, the s...
2020-12-01 23:57
7217
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board
SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the strengthening of its Scientific Advisory Board ("SAB"...
2020-12-01 21:00
3224
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116